- ￥2980
- Bioss
- bs-3550R-PerCP-Cy7
- 2025年09月30日
- 产品信息以Bioss网站为准
企业认证
相关产品推荐更多 >
EHBP1L1 Rabbit pAb, Cy5 conjugated(bs-14524R-Cy5)-100ul
￥2980ASPP2 Rabbit pAb, PE-Cy7 conjugated(bs-1283R-PE-Cy7)-100ul
￥2980
LZTS1 Rabbit pAb, Cy5 conjugated(bs-5705R-Cy5)-100ul
￥2980CDK5R1/p35 Rabbit pAb, BF647 conjugated(bs-11611R-BF647)-100ul
￥2980
RAVER2 Rabbit pAb, BF488 conjugated(bs-19739R-BF488)-100ul
￥2980
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 应用范围：
产品信息以Bioss网站为准
- 规格：
100ul
| 产品编号 | bs-3550R-PerCP-Cy7 |
| 英文名称 | Myogenin Rabbit pAb, PerCP-Cy7 conjugated |
| 中文名称 | PerCP-Cy7标记的肌细胞生成素抗体 |
| 英文别名 | MYOG_HUMAN; MYOG; BHLHC3; MYF4; Class C basic helix-loop-helix protein 3(bHLHc3); Myogenic factor 4(Myf-4); BHLHC3; MYF4; MYF 4; |
| 产品应用 | IF=1:100-500, ICC/IF=1:50-200 Not yet tested in other applications. |
| 抗体来源 | Rabbit |
| 免疫原 | KLH conjugated synthetic peptide derived from human MYOG/Myogenin |
| 亚型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 克隆类型 | Polyclonal |
| 浓度 | 1mg/ml |
| 储存液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 研究领域 | Epigenetics and Nuclear Signaling > Transcription > Domain Families > HLH / Leucine Zipper > HLH Stem Cells > Mesenchymal Stem Cells > Myogenesis |
| 亚基 | Homodimer and heterodimer with E12; heterodimerization enhances MYOG DNA-binding and transcriptional activities. Interacts with SMARCA4/BRG1/BAF190A. Interacts (via C-terminus region) with SSRP1 and SUPT16H; the interaction is indicative of an interaction with the FACT complex. |
| 亚细胞定位 | Nucleus. Note=Recruited to late myogenic gene promoter regulatory sequences with SMARCA4/BRG1/BAF190A and SWI/SNF chromatin-remodeling enzymes to promote chromatin-remodeling and transcription initiation in developing embryos. |
| 翻译后修饰 | Phosphorylated by CAMK2G on threonine and serine amino acids in a muscle activity-dependent manner. Phosphorylation of Thr-87 impairs both DNA-binding and trans-activation functions in contracting muscles. |
| 相似性 | Contains 1 bHLH (basic helix-loop-helix) domain. |
| 功能 | Acts as a transcriptional activator that promotes transcription of muscle-specific target genes and plays a role in muscle differentiation, cell cycle exit and muscle atrophy. Essential for the development of functional embryonic skeletal fiber muscle differentiation. However is dispensable for postnatal skeletal muscle growth; phosphorylation by CAMK2G inhibits its transcriptional activity in respons to muscle activity. Required for the recruitment of the FACT complex to muscle-specific promoter regions, thus promoting gene expression initiation. During terminal myoblast differentiation, plays a role as a strong activator of transcription at loci with an open chromatin structure previously initiated by MYOD1. Together with MYF5 and MYOD1, co-occupies muscle-specific gene promoter core regions during myogenesis. Cooperates also with myocyte-specific enhancer factor MEF2D and BRG1-dependent recruitment of SWI/SNF chromatin-remodeling enzymes to alter chromatin structure at myogenic late gene promoters. Facilitates cell cycle exit during terminal muscle differentiation through the up-regulation of miR-20a expression, which in turn represses genes involved in cell cycle progression. Binds to the E-box containing (E1) promoter region of the miR-20a gene. Plays also a role in preventing reversal of muscle cell differentiation. Contributes to the atrophy-related gene expression in adult denervated muscles. Induces fibroblasts to differentiate into myoblasts. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 背景资料 | Myogenin is a member of a family of myogenic regulatory genes, which includes MyoD, myf5 and MRF4. These genes encode a set of transcription factors, which are essential for muscle development. Transfection of myogenin into multipotential mesodermal cells have been shown to convert the mesodermal cells to myoblasts. Expression of myogenin is restricted to cells of skeletal muscle origin. It is therefore a useful marker for tumors of the muscle lineage, being strongly expressed in alveolar rhabdomyosarcomas. |
| 应用 | 推荐稀释比例 |
| {IF} | {1:100-500} |
| {ICC/IF} | {1:50-200} |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
Myogenin Rabbit pAb, PerCP-Cy7 conjugated(bs-3550R-PerCP-Cy7)-100ul
￥2980
